WATCH: Pfizer CEO Albert Bourla Discusses FDA-Approved “Electronic Pill” With a Microchip at World Economic Forum

Remember when micro-chipping was a crazy conspiracy theory?

If you mentioned the possibility of anyone planting a chip inside you, it would earn you the lunatic label by the mainstream media.

As it turns out, placing a microchip inside humans isn’t a conspiracy theory after all.

Unsurprisingly, it’s the same cast of characters that discuss the scientific experiments they’d like to perform on humanity.

In this case, Pfizer CEO Albert Bourla made these remarks at the World Economic Forum three years ago:

Pfizer CEO Bourla talking about the microchip that will be in medications. Sounds normal right?? Just a conspiracy theory?? #Pfizer #vaccines pic.twitter.com/ZfocFKIavH

— Matt – (@mattbucknelltx) December 16, 2021

An FDA-approved “electronic pill” with a biological chip in the tablet?

Once the pill dissolves in your stomach, it sends a signal that can track you.

Bourla doesn’t hide the microchip’s purpose is to enforce patient compliance.

Bourla: "FDA approved the first electronic pill."
Freedom is slavery. Control is health. And ignorance is always strength. https://t.co/jj7YrPgN7i

— GKB Weber (@GkbWeber) December 16, 2021

https://twitter.com/DoniTheDon_/status/1471575085723095054

Pfizer CEO: “FDA approved the first electronic pill”
I'm not a conspiracy theorist but correct me if i'm wrong didn't Bill Gates the owner of Microsoft Operating System massively fund Pfizer? I'm not touching any pill that's electronic.
👇🙄 pic.twitter.com/zZs1Md6YCT

— Shaun (@skbytes) December 17, 2021

Abilify MyCite is most likely the “electronic pill” Bourla references in the clip.

The FDA approved the pill in 2017.

💊"The Food and Drug Administration has approved the first digital pill for the US which tracks if patients have taken their medication." 💊

https://t.co/4eiaTq2JSS#Privacy#Medicine#FDA#AbilifyMyCite#Healthcare

— Grace 🔎 (@reallygraceful) November 14, 2017

FDA approves Otsuka/Proteus' Abilify MyCite –> first digital medicinehttps://t.co/KYYozpxWRN

Microchip sensor-containing pill to increase compliance pic.twitter.com/4NWWHkE7QI

— Andy Biotech (@AndyBiotech) November 14, 2017

In the future, your pills tell your doctor if you took them. FDA just approved a sensor-containing version of the antipsychotic Abilify, Abilify MyCite.

— Matthew Herper (@matthewherper) November 13, 2017

Abilify MyCite is now on the market, it's the first psychiatric drug with a digital sensor to track whether someone has taken the drug, then share that info with whoever is programmed to receive it. The potential for civil rights abuses is tremendous.https://t.co/VxCslWEUsD

— Amanda Gelender חַנָּה 🔮 (@agelender) February 1, 2018

Here’s the FDA News Release:

The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

The system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the medication on their smart phone. Patients can also permit their caregivers and physician to access the information through a web-based portal.

“Being able to track ingestion of medications prescribed for mental illness may be useful for some patients,” said Mitchell Mathis, M.D., director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “The FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers.”

It is important to note that Abilify MyCite’s prescribing information (labeling) notes that the ability of the product to improve patient compliance with their treatment regimen has not been shown. Abilify MyCite should not be used to track drug ingestion in “real-time” or during an emergency because detection may be delayed or may not occur.

NATIONAL POLL: Do You Still Have Trump's Back 100%?

Schizophrenia is a chronic, severe and disabling brain disorder. About 1 percent of Americans have this illness. Typically, symptoms are first seen in adults younger than 30 years of age. Symptoms of those with schizophrenia include hearing voices, believing other people are reading their minds or controlling their thoughts, and being suspicious or withdrawn. Bipolar disorder, also known as manic-depressive illness, is another brain disorder that causes unusual shifts in mood, energy, activity levels and the ability to carry out day-to-day tasks. The symptoms of bipolar disorder include alternating periods of depression and high or irritable mood, increased activity and restlessness, racing thoughts, talking fast, impulsive behavior and a decreased need for sleep.

Abilify MyCite contains a Boxed Warning alerting health care professionals that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify MyCite is not approved to treat patients with dementia-related psychosis. The Boxed Warning also warns about an increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants. The safety and effectiveness of Abilify MyCite have not been established in pediatric patients. Patients should be monitored for worsening and emergence of suicidal thoughts and behaviors. Abilify MyCite must be dispensed with a patient Medication Guide that describes important information about the drug’s uses and risks.

In the clinical trials for Abilify, the most common side effects reported by adults taking Abilify were nausea, vomiting, constipation, headache, dizziness, uncontrollable limb and body movements (akathisia), anxiety, insomnia, and restlessness. Skin irritation at the site of the MyCite patch placement may occur in some patients.

Prior to initial patient use of the product, the patient’s health care professional should facilitate use of the drug, patch and app to ensure the patient is capable and willing to use the system.

Abilify was first approved by the FDA in 2002 to treat schizophrenia. The ingestible sensor used in Abilify MyCite was first permitted for marketing by the FDA in 2012.

The FDA granted the approval of Abilify MyCite to Otsuka Pharmaceutical Co., Ltd. The sensor technology and patch are made by Proteus Digital Health.